Type I interferon signature in systemic lupus erythematosus.

作者：Shira Rosenberg Bezalel, Keren Mahlab Guri, Daniel Elbirt, Ilan Asher, Zev Moshe Sthoeger · 发表于：PubMed · 年份：2014 · 被引用次数：49 · 研究领域：Systemic Lupus Erythematosus Research、Cytokine Signaling Pathways and Interactions、Immune Cell Function and Interaction

Type I interferons (IFN) are primarily regarded as an inhibitor of viral replication. However, type I IFN, mainly IFNalpha, plays a major role in activation of both the innate and adaptive immune systems. Systemic lupus erythematosus (SLE) is a chronic, multi-systemic, inflammatory autoimmune disease with undefined etiology. SLE is characterized by dysregulation of both the innate and the adaptive immune systems. An increased expression of type I IFN-regulated genes, termed IFN signature, has been reported in patients with SLE. We review here the role of IFNalpha in the pathogenesis and course of SLE and the possible role of IFNalpha inhibition as a novel treatment for lupus patients.